Editorial companion

What stands out

Amgen plunged after Novartis reported its heart drug pelacarsen failed a pivotal trial, sending a ripple through makers of cardiovascular therapies, while Oracle rallied on growing analyst optimism ahead of its post-close results. Bloomberg highlighted both moves alongside an index-driven pop for Bloom Energy, a neat microcosm of the market: binary clinical risk versus earnings-driven momentum. For investors choosing between steady cash flow stories and headline-prone drug names, the clip is a reminder that the same calendar can produce very different kinds of risk and opportunity.